falsefalse

Lower-Risk MDS: Current and Future Treatment Strategies - Episode 3

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

, ,

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment
    EP. 2: Clinical Insights into the COMMANDS Trial
    Now Viewing
    EP. 3: Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?
    EP. 4: MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS
    EP. 5: Recent Updates for Second-Line Treatment Options in Lower-Risk MDS
    EP. 6: Clinical Implications of Recent Data on New Agents in Lower-Risk MDS
    EP. 7: Real-World Data for Luspatercept in Lower-Risk MDS
    EP. 8: Treatment Strategies and Sequencing in MDS
    EP. 9: Unmet Needs and Future of Lower-Risk MDS

    Related Content:

    Lower-Risk MDS: Current and Future Treatment StrategiesMoffitt Cancer CenterHematologic OncologyInsights
    Looking Into the Future and at Unmet Needs in EGFRm NSCLC
    Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer
    Managing Adverse Events With Different TKIs
    x